SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Sep 24, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-009929.pdf 0001179110-20-009929.rtf 0001179110-20-009929.xls
Sep 24, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-009930.pdf 0001179110-20-009930.rtf 0001179110-20-009930.xls
Sep 24, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-009931.pdf 0001179110-20-009931.rtf 0001179110-20-009931.xls
Sep 22, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-011228.pdf 0001558370-20-011228.rtf 0001558370-20-011228.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Sep 21, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-011205.pdf 0001558370-20-011205.rtf 0001558370-20-011205.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Sep 21, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-009900.pdf 0001179110-20-009900.rtf 0001179110-20-009900.xls
Sep 21, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-009901.pdf 0001179110-20-009901.rtf 0001179110-20-009901.xls
Sep 08, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-011026.pdf 0001558370-20-011026.rtf 0001558370-20-011026.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Sep 04, 2020	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001179110-20-009584.pdf 0001179110-20-009584.rtf 0001179110-20-009584.xls
Sep 01, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-010927.pdf 0001558370-20-010927.rtf 0001558370-20-010927.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination